Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group

Purpose Highly sensitized patients with a high level of panel reactive antibody (PRA) experience more episodes of antibody-mediated rejection (AMR) and poorer graft survival than non-sensitized patients. Rituximab is a well-known monoclonal anti-CD20 antibody that causes the depletion of B lymphocytes. The aim of this study was to compare a rituximab-administered and a non-administered group of highly sensitized recipients. Methods Forty-three kidney recipients with a PRA level of ≥50% were included. Sixteen (group R) received one dose of rituximab at 2 days prior to transplantation and 27 patients (group NR) did not. Results Patients' demographics, such as age, sex, dialysis duration, and type of immunosuppressive agent were not different in the two groups. No side effects due to rituximab administration were observed in group R. Class I PRA of group R (75.6 ± 37.7%) was higher than that of group NR (45.7 ± 35.8%, P = 0.013). More acute rejection episodes occurred within 1 year after transplantation in group NR but the difference between the groups was not significant (18.8% in group R vs. 29.6% in group NR, P = 0.631). However, two AMR episodes occurred only in group NR. Renal functions were not different in the two groups. In group R, CD19 and CD20 rapidly decreased 2 days after rituximab infusion. Furthermore, the administration of rituximab was not linked to acute rejection. Conclusion To confirm the long-term anti-rejection and beneficial effects of rituximab, further studies should be performed with a larger cohort. In conclusion, rituximab administration 2 days prior to transplantation is both effective and safe.

[1]  Yon Seon Kim Parathyroid carcinoma with lung metastasis in a thirteen-year-old girl , 2012, Journal of the Korean Surgical Society.

[2]  H. Genberg,et al.  A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation , 2009, Transplantation.

[3]  Y. Yamaguchi,et al.  Impact of low‐dose rituximab on splenic B cells in ABO‐incompatible renal transplant recipients , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  So young Lee,et al.  Successful Renal Transplantation with Desensitization in Highly Sensitized Patients: A Single Center Experience , 2009, Journal of Korean medical science.

[5]  A. S. Muñoz,et al.  Rituximab in highly sensitized kidney transplant recipients. , 2008, Transplantation proceedings.

[6]  L. Rostaing,et al.  Rituximab therapy for acute humoral rejection after kidney transplantation. , 2007, Transplantation.

[7]  A. Wernerson,et al.  Pharmacodynamics of Rituximab in Kidney Allotransplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  M. Pescovitz,et al.  Presensitization: the problem and its management. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[9]  A. Salama,et al.  Drug Insight: rituximab in renal disease and transplantation , 2006, Nature Clinical Practice Nephrology.

[10]  M. Stegall,et al.  A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  S. Hariharan,et al.  Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab , 2005, Clinical transplantation.

[12]  Y. Becker,et al.  Rituximab as Treatment for Refractory Kidney Transplant Rejection , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  T. Illidge,et al.  Apparent modulation of CD20 by rituximab: an alternative explanation. , 2004, Blood.

[14]  N. Fineberg,et al.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.

[15]  H. Kantarjian,et al.  Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. , 2003, Blood.

[16]  M. Sarwal,et al.  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. , 2003, The New England journal of medicine.

[17]  M. Fishbein,et al.  Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  C. Cunningham-Rundles,et al.  Utility of Intravenous Immune Globulin in Kidney Transplantation: Efficacy, Safety, and Cost Implications , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  J. Aranda,et al.  Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. , 2002, Transplantation.

[20]  Francis L. Delmonico,et al.  ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1 , 2001, Transplantation.

[21]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Terasaki,et al.  Sensitization effect. , 1986, Clinical transplants.